AZSTARYS is the
FIRST and ONLY
d-MPH with novel SDX prodrug
and IR activity1,2
aFollowing a single dose of AZSTARYS in healthy adults under fasted conditions.
Mean plasma concentrations continued to gradually decline through 72 hours post dose.1
Select a profile
Name: Sean
Age: 25 years
Sex: Male
Current treatment: MPH ER stimulant
Name: Sarah
Age: 42 years
Sex: Female
Current treatment: None
Source: IQVIA XPD prescriber dynamics data 7/1/2021 through 4/8/2022.
Trademarks and copyrights belong to their respective owners.
ADHD, Attention Deficit Hyperactivity Disorder; AMP, amphetamine; d-MPH, dexmethylphenidate; ER, extended-release; HCl, hydrochloride; IR, Immediate-release;
MPH, methylphenidate; PK, pharmacokinetics; SDX, serdexmethylphenidate.
References: 1. AZSTARYS. Prescribing information. Corium, Inc; 2021. 2. Mickle T, Guenther S, Chi G, inventors; KemPharm, Inc, assignee. Methylphenidate-prodrugs, processes of making and using the same. U.S. patent 10,584,113. March 10, 2020. 3. Childress AC, Komolova M, Sallee FR. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin Drug Metab Toxicol. 2019;15(11):937-974. doi:10.1080/17425255.2019.1675636 4. Patrick KS, Radke JL, Raymond JR, et al. Drug regimen individualization for attention-deficit/hyperactivity disorder: guidance for methylphenidate and dexmethylphenidate formulations. Pharmacotherapy. 2019;39(6):677-688. doi:10.1002/phar.2190 5. Data on file. Corium, Inc.
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder
(ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE
Please click here for Full
Prescribing Information,
including Boxed WARNING.
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE